Abstract: Compositions and methods for urea silicone gels for treating hyperkeratotic skin diseases that may benefit from barrier protection and from urea silicone gel's ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gels may be excessive dryness, callus, corns, old and new scars, and keloids, among others. Disclosed urea silicone gels may include micronized urea USP, and an anhydrous silicone base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol, which may increase skin permeability to urea. Additionally, because of the high content of unsaturated fatty acids of pracaxi oil and seje oil, disclosed urea silicone gel may exhibit an enhanced hydrating effect on skin cells, over-moisturizing and hydrating tough, thick hyperkeratotic conditions.

Abstract: The present disclosure relates to a method for validating formulations in pharmaceutical compositions. The method may include entering inventory into the system, formulating the batch, storing batch compounding data, manufacturing the batch, assigning and printing a barcode on the pharmaceutical compositions, scanning the barcode, checking if correct chemicals are used, and correcting the pharmaceutical compositions formulation if required. The present method may prevent a batch to be produced until the batch has been corrected in cases where incorrect chemicals are used in pharmaceutical compositions, and may additionally improve accuracy and efficiency of quality control because data, such as lot numbers, does not have to be hand-typed when barcodes are scanned.

Abstract: The present disclosure describes a topical scar treatment composition that may include tamoxifen citrate in a concentration of about 0.01% by weight to about 1% by weight, with about 0.1% by weight being preferred, and an anhydrous silicone base for enhancing skin permeation and scar removing effects, in a concentration of about 10% by weight to about 100% by weight, with about 100% being preferred being preferred. The small concentration of tamoxifen citrate may prevent dangerous side effects and may be successful in treating abnormal scars such as keloids and hypertrophic scars.

Abstract: Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane.

Abstract: A method for validating pharmaceutical compositions' weight is disclosed. The method may involve a pharmaceutical composition weight validation system, which may include a pharmaceutical manufacturing process, a barcode scanning, weighing the pharmaceutical compositions with a pharmaceutical balance, sending the barcode scanning and weight information to a database, and having a user accessing the information through a user interface. Additionally, the method for validating pharmaceutical compositions' weight may include entering inventory into the system, formulating the batch, storing weight information, manufacturing the batch, assigning and printing a barcode on the pharmaceutical products, scanning the barcode, weighing the pharmaceutical compositions, populating and storing the weight data, checking if weight is correct in pharmaceutical compositions, and correcting the weight of pharmaceutical compositions.

Abstract: Compositions and methods for urea silicone gels for treating skin conditions that may benefit from barrier protection and from urea silicone gel ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gel may be excessive dryness, insect bites, keloids and scars, among others. Disclosed urea silicone gel may include micronized urea USP, an anhydrous silicone base, and a PEG ointment base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol that may increase skin permeability to urea. PEG ointment base may be water-washable and includes meadowsweet extract. Additionally, PEG urea silicone gel may provide occlusion, and may maintain a moist environment within the skin condition which allows optimal healing. Pain also may be decreased by maintaining a moist environment.

Abstract: The present disclosure relates to a workflow method that may be utilized in pharmacies involving compounding operations. The method may classify prescriptions depending on the need to compound them, and may thereafter assign the location of the different pharmaceutical compositions for pharmacy personnel to retrieve them, or may locate the different chemicals needed to compound the required pharmaceutical compositions if the desired pharmaceutical compositions are not available in inventory. The present workflow method may manage an unlimited number of activities depending on the pharmacy workload, pharmacy layout, and types of pharmaceutical compositions. The present workflow method may increase accuracy and efficiency of pharmaceutical operations.

Abstract: A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 0.05-5% w/w of one or more phospholipids, 1-20% w/w of one or more oils having essential fatty acids, behenic acid, and oleic acid, 0.1-3% w/w of one or more skin lipids, and 1-10% w/w of a butter having linoleic acid and linolenic acid. One of the oils used in the composition is Pracaxi oil.

Abstract: A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 10-50% of Pracaxi oil, 15-40% of Patauá oil, 10-30% of Inaja oil, and 10-30% of one of more emollients.

Abstract: Method for producing liposomes in a composition for skin permeation are provided. A composition that includes water, skin lipids, butters having linoleic acid and linolenic acid, Pracaxi oil, Plukenetia Volubilis seed oil, and phospholipids is provided. The composition is dispersed in a vessel using a high shear homogenizer. Negative pressure is created in the vessel such that liposomes of 5-20 microns are produced thereby providing for increased skin permeation of active ingredients added to the composition.

Abstract: A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 0.05-5% w/w of one or more phospholipids, 1-20% w/w of one or more oils having essential fatty acids, behenic acid, and oleic acid, 0.1-3% w/w of one or more skin lipids, and 1-10% w/w of a butter having linoleic acid and linolenic acid. One of the oils used in the composition is Pracaxi oil.

Abstract: A composition to be used as a natural preservative is provided. The composition comprises 1.0 to 20% w/w one or more naturally occurring substances containing salicylate, 0.1 to 20% w/w one or more species of lonicera, 0.1 to 80% w/w one or more leuconostoc, and 0.1 to 10% w/w gluconic acid. The composition has antimicrobial properties and is in a liquid form.

Abstract: A capsule handling system is formed of a loader component and an opener/encapsulater component. The system can handle different sized capsules, and has interchangeable parts so that a compounding pharmacist can conveniently produce a variety of distinct filled capsules, on the order of a prescribing medical professional to meet the unique needs of patients.

Abstract: A capsule handling system is formed of a loader component and an opener/encapsulater component. The system can handle different sized capsules, and has interchangeable parts so that a compounding pharmacist can conveniently produce a variety of distinct filled capsules, on the order of a prescribing medical professional to meet the unique needs of patients.

Abstract: A combination medication mold and dispenser. The medication is poured into a multicompartment tray and solidifies into troches. The tray is made of a flexible plastic which can be bent to release the troches individually. The tray has a cover attached with a flexible hinge to protect the troches after preparation. The medication can be prepared and dispensed to the patient in the same container. The covered tray can be held in a sleeve to further protect the medication and hold the cover in place.